1. Home
  2. MBIO vs CINGW Comparison

MBIO vs CINGW Comparison

Compare MBIO & CINGW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MBIO
  • CINGW
  • Stock Information
  • Founded
  • MBIO 2015
  • CINGW N/A
  • Country
  • MBIO United States
  • CINGW United States
  • Employees
  • MBIO N/A
  • CINGW 13
  • Industry
  • MBIO Biotechnology: Pharmaceutical Preparations
  • CINGW Biotechnology: Pharmaceutical Preparations
  • Sector
  • MBIO Health Care
  • CINGW Health Care
  • Exchange
  • MBIO Nasdaq
  • CINGW Nasdaq
  • Market Cap
  • MBIO N/A
  • CINGW N/A
  • IPO Year
  • MBIO N/A
  • CINGW 2021
  • Fundamental
  • Price
  • MBIO $0.21
  • CINGW $0.04
  • Analyst Decision
  • MBIO Strong Buy
  • CINGW
  • Analyst Count
  • MBIO 1
  • CINGW 0
  • Target Price
  • MBIO $2.00
  • CINGW N/A
  • AVG Volume (30 Days)
  • MBIO 1.3M
  • CINGW N/A
  • Earning Date
  • MBIO 11-08-2024
  • CINGW N/A
  • Dividend Yield
  • MBIO N/A
  • CINGW N/A
  • EPS Growth
  • MBIO N/A
  • CINGW N/A
  • EPS
  • MBIO N/A
  • CINGW N/A
  • Revenue
  • MBIO N/A
  • CINGW N/A
  • Revenue This Year
  • MBIO N/A
  • CINGW N/A
  • Revenue Next Year
  • MBIO N/A
  • CINGW N/A
  • P/E Ratio
  • MBIO N/A
  • CINGW N/A
  • Revenue Growth
  • MBIO N/A
  • CINGW N/A
  • 52 Week Low
  • MBIO $0.13
  • CINGW N/A
  • 52 Week High
  • MBIO $1.68
  • CINGW N/A
  • Technical
  • Relative Strength Index (RSI)
  • MBIO 33.47
  • CINGW N/A
  • Support Level
  • MBIO $0.20
  • CINGW N/A
  • Resistance Level
  • MBIO $0.23
  • CINGW N/A
  • Average True Range (ATR)
  • MBIO 0.02
  • CINGW 0.00
  • MACD
  • MBIO -0.01
  • CINGW 0.00
  • Stochastic Oscillator
  • MBIO 5.19
  • CINGW 0.00

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: